Triggers and alleviating factors for fatigue in Parkinson's disease.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
18
07
2020
accepted:
24
12
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
27
7
2021
Statut:
epublish
Résumé
Fatigue is common in Parkinson's Disease, but few effective treatments are available for it. Exploring triggers and alleviating factors, including effects of exercise, could inform development of management strategies for Parkinson's Disease fatigue. To examine triggers and alleviating factors for fatigue reported by individuals with Parkinson's Disease, including perceived effect of exercise. A sample of individuals with self-reported Parkinson's Disease participating in the study Fox Insight were administered an online survey. The survey included the Parkinson's Fatigue Scale, the Physical Activity Scale for the Elderly, and multiple-choice questions about triggers and alleviating factors for fatigue. Among the sample of 1,029 individuals with Parkinson's disease, mean (standard deviation (SD)) age was 67.4 (9.3) years, 44.0% were female. Parkinson's Fatigue Scale score ranged from 16-80, mean (SD) 48.8 (16.2). Poor sleep (62.1%) and physical exertion (45.1%) were frequently reported triggers for fatigue. Coping strategies including sitting quietly (58.1%), laying down with or without napping, and exercise (20%). Physical Activity Scale for the Elderly scores were higher in those who reported that exercise alleviated their fatigue (49.7%) compared to those who reported it worsened their fatigue (18.9%) (mean (SD) score 158.5 (88.8) vs 119.8 (66.6) respectively; p<0.001). Several behavioral and environmental triggers and alleviating strategies for fatigue are reported by individuals with Parkinson's disease. Many feel that exercise alleviates fatigue, though the relationship between exercise and fatigue in Parkinson's Disease appears complex. This exploratory study may inform future development of treatments or coping strategies for Parkinson's disease fatigue.
Sections du résumé
BACKGROUND
Fatigue is common in Parkinson's Disease, but few effective treatments are available for it. Exploring triggers and alleviating factors, including effects of exercise, could inform development of management strategies for Parkinson's Disease fatigue.
OBJECTIVES
To examine triggers and alleviating factors for fatigue reported by individuals with Parkinson's Disease, including perceived effect of exercise.
METHODS
A sample of individuals with self-reported Parkinson's Disease participating in the study Fox Insight were administered an online survey. The survey included the Parkinson's Fatigue Scale, the Physical Activity Scale for the Elderly, and multiple-choice questions about triggers and alleviating factors for fatigue.
RESULTS
Among the sample of 1,029 individuals with Parkinson's disease, mean (standard deviation (SD)) age was 67.4 (9.3) years, 44.0% were female. Parkinson's Fatigue Scale score ranged from 16-80, mean (SD) 48.8 (16.2). Poor sleep (62.1%) and physical exertion (45.1%) were frequently reported triggers for fatigue. Coping strategies including sitting quietly (58.1%), laying down with or without napping, and exercise (20%). Physical Activity Scale for the Elderly scores were higher in those who reported that exercise alleviated their fatigue (49.7%) compared to those who reported it worsened their fatigue (18.9%) (mean (SD) score 158.5 (88.8) vs 119.8 (66.6) respectively; p<0.001).
CONCLUSIONS
Several behavioral and environmental triggers and alleviating strategies for fatigue are reported by individuals with Parkinson's disease. Many feel that exercise alleviates fatigue, though the relationship between exercise and fatigue in Parkinson's Disease appears complex. This exploratory study may inform future development of treatments or coping strategies for Parkinson's disease fatigue.
Identifiants
pubmed: 33540422
doi: 10.1371/journal.pone.0245285
pii: PONE-D-20-22321
pmc: PMC7861907
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245285Subventions
Organisme : NIA NIH HHS
ID : P30 AG024827
Pays : United States
Déclaration de conflit d'intérêts
The authors have read the journal’s policy and have the following competing interests: The Michael J Fox Foundation (MJFF), which sponsored this study, is funded by ACADIA Pharmaceuticals, Adamas Pharmaceuticals, Intec Pharma, Lundbeck Inc., and Sunovion Pharmaceutical. Author SM receives research support from MJFF, from the Parkinson Foundation (PF), and from Cerevel Therapeutics, was a paid consultant to MJFF, is a study site investigator for a study sponsored by Neuraly Rho, is a study site sub-investigator for a study sponsored by Biogen, and received consulting fees from Deep Brain Innovations, LLC. Author CM receives research support from MJFF, from the Canadian Institutes of Health Research, from PF, and from the International Parkinsons and Movement Disorder Society, and is a site investigator for a research study supported by Theravance Biopharma. Author LMC receives research support from MJFF, receives research support from the UPMC Competitive Medical Research Fund, is study site investigator for a study sponsored by Biogen, receives research support from the National Institutes of Health, receives royalties from Elsevier (for authorship), and receives royalties from Wolters Kluwel (for authorship). Authors CK and MD are or were previously employed by the MJFF. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.
Références
Mov Disord. 2010 Dec 15;25(16):2704-16
pubmed: 20931631
J Parkinsons Dis. 2017;7(1):193-202
pubmed: 27858719
Mov Disord. 2013 Sep 15;28(11):1587-96
pubmed: 24132847
Neuromuscul Disord. 2012 Dec;22 Suppl 3:S208-13
pubmed: 23182641
Sci Data. 2020 Feb 24;7(1):67
pubmed: 32094335
Mov Disord. 2016 Oct;31(10):1497-1505
pubmed: 27145402
Neurology. 2017 Oct 24;89(17):1795-1803
pubmed: 28954882
J Sleep Res. 2009 Jun;18(2):272-81
pubmed: 19645971
J Parkinsons Dis. 2017;7(4):703-711
pubmed: 29103050
Mov Disord Clin Pract. 2014 Sep 01;1(4):307-316
pubmed: 30363881
Eur Neurol. 2012;67(6):326-30
pubmed: 22555623
J Parkinsons Dis. 2018;8(1):107-111
pubmed: 29480222
Neurorehabil Neural Repair. 2009 Jul-Aug;23(6):600-8
pubmed: 19131578
JAMA Neurol. 2013 Feb;70(2):183-90
pubmed: 23128427
Dyn Med. 2005 Mar 03;4(1):3
pubmed: 15745455
J Rehabil Med. 2008 Apr;40(4):241-7
pubmed: 18382818
Parkinsonism Relat Disord. 2005 Jan;11(1):49-55
pubmed: 15619463
J Psychosom Res. 2011 Apr;70(4):328-34
pubmed: 21414452
Mov Disord. 2014 Nov;29(13):1675-8
pubmed: 25234443
J Appl Physiol (1985). 2014 Mar 1;116(5):582-92
pubmed: 24408997
Mov Disord. 2012 Jan;27(1):143-6
pubmed: 21953509
Neurol Sci. 2018 Dec;39(12):2169-2174
pubmed: 30255487
Mov Disord. 2016 Jan;31(1):23-38
pubmed: 26715466
Mov Disord. 2013 Aug;28(9):1230-40
pubmed: 23536417
J Clin Epidemiol. 1999 Jul;52(7):643-51
pubmed: 10391658
Phys Ther. 2013 May;93(5):628-36
pubmed: 23288910
Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145
pubmed: 23152233
J Neurol. 2014 Feb;261(2):382-91
pubmed: 24375016
Parkinsonism Relat Disord. 2007 Oct;13(7):443-5
pubmed: 17055331
Mov Disord. 2006 Aug;21(8):1073-7
pubmed: 16637049
Arch Phys Med Rehabil. 2008 Jul;89(7):1221-9
pubmed: 18534554
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Parkinsonism Relat Disord. 2019 Apr;61:118-125
pubmed: 30554993
Neurology. 2008 Aug 12;71(7):481-5
pubmed: 18695158
Lancet Neurol. 2010 Jun;9(6):573-80
pubmed: 20452823
Parkinsonism Relat Disord. 2014 May;20(5):549-53
pubmed: 24637120
Eur J Neurol. 2012 Jul;19(7):963-8
pubmed: 22340430
Int Rev Neurobiol. 2017;134:947-971
pubmed: 28805590
Mov Disord. 2009 Jul 30;24(10):1512-8
pubmed: 19514069
Arthritis Rheum. 2005 Oct 15;53(5):697-702
pubmed: 16208668
Parkinsonism Relat Disord. 2016 Feb;23:45-9
pubmed: 26683744
Intern Med. 2011;50(15):1553-8
pubmed: 21804280
J Neurol. 2013 Jun;260(6):1554-61
pubmed: 23299623
Cochrane Database Syst Rev. 2016 Feb 07;2:CD003200
pubmed: 26852189
Mov Disord. 2001 Mar;16(2):190-6
pubmed: 11295769
Mov Disord. 2007 Feb 15;22(3):297-308
pubmed: 17133511
Mov Disord. 2011 Oct;26 Suppl 3:S42-80
pubmed: 22021174
J Clin Sleep Med. 2017 May 15;13(5):685-692
pubmed: 28260591
Contemp Clin Trials. 2013 Sep;36(1):90-8
pubmed: 23770108
J Neurol Sci. 2017 Mar 15;374:38-41
pubmed: 28087059
Neurology. 2004 Nov 23;63(10):1908-11
pubmed: 15557510
Eur Neurol. 2013;70(3-4):201-9
pubmed: 23969578
Cochrane Database Syst Rev. 2015 Oct 08;(10):CD010925
pubmed: 26447539
Mov Disord. 2003 Dec;18(12):1459-63
pubmed: 14673882
Brain. 2010 Nov;133(11):3434-43
pubmed: 20884645
Parkinsonism Relat Disord. 2013 Nov;19(11):1027-32
pubmed: 23916654
J Neurol Phys Ther. 2019 Jan;43(1):12-25
pubmed: 30531382
Parkinsons Dis. 2015;2015:586378
pubmed: 25722915
Mov Disord. 2009 Aug 15;24(11):1641-9
pubmed: 19514014
Mov Disord. 2010 Nov 15;25(15):2493-500
pubmed: 20922807
Transl Neurodegener. 2016 May 10;5:9
pubmed: 27175281
Neurology. 2013 Feb 26;80(9):800-9
pubmed: 23365054
J Parkinsons Dis. 2012;2(2):167-70
pubmed: 23939441
BMC Neurol. 2014 Jan 24;14:19
pubmed: 24456482
Neurology. 2011 Jul 19;77(3):288-94
pubmed: 21768599
Neurology. 2002 Aug 13;59(3):408-13
pubmed: 12177375
Mov Disord. 2010 May 15;25(7):805-22
pubmed: 20461797
Neurology. 2016 Jun 14;86(24):2278-83
pubmed: 27170564
Sleep. 2003 Dec 15;26(8):1049-54
pubmed: 14746389
Mov Disord. 2008 Apr 15;23(5):631-40
pubmed: 18181210
Mov Disord. 1999 Mar;14(2):237-41
pubmed: 10091615
Mov Disord. 2016 May;31(5):625-31
pubmed: 26879133